Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 12, 2016
- Revision received December 6, 2016
- Accepted December 7, 2016
- Published online January 7, 2017.
Copyright & Usage
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Author Information
- 1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
- 2Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
- 3Department of Radiotherapy, Dr. Bernard Verbeeten Institute, Tilburg, the Netherlands
- 4Department of Radiotherapy, University Medical Center Eppendorf, Hamburg, Germany
- Correspondence to: Professor Dirk Rades, MD, Department of Radiation Oncology, University of Lübeck, Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany. Tel: +49 4515006661, Fax: +49 4515003324, e-mail: rades.dirk{at}gmx.net
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer
- Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases
- Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer
- Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM
- Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses
- Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter?
- Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer
- Contribution of Patient-reported Symptoms Before Palliative Radiotherapy to Development of Multivariable Prognostic Models
- Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases